A Pilot Open-label Study of Aldose Reductase Inhibition with AT-001 (caficrestat) in Patients Hospitalized for COVID-19 Infection: Results from a Registry-based Matched-control Analysis

Mostrar otras versiones (1)

BACKGROUND: Cardiometabolic disease may confer increased risk of adverse outcomes in COVID-19 patients by activation of the aldose reductase pathway, a trigger of the inflammatory cascade. We hypothesized that aldose reductase inhibition with AT-001 (caficrestat) might represent a novel therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaztanaga, Juan, Ramasamy, Ravichandran, Schmidt, Ann Marie, Fishman, Glenn, Shendelman, Shoshana, Thangavelu, Karthinathan, Perfetti, Riccardo, Katz, Stuart D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Mosby, Inc. 2021
Materias:
0029
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556500/
http://dx.doi.org/10.1016/j.ahj.2021.10.022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556500/
http://dx.doi.org/10.1016/j.ahj.2021.10.022

Ejemplares similares